🇺🇸 FDA
Patent

US 10562960

Neutralizing antibodies to gp120 and their use

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 10562960 (Neutralizing antibodies to gp120 and their use) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
41
CPC classes
A61K, A61K2039/505, A61K2039/545, A61P, A61P31/18